• SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Gujarat Kidney & Super Speciality Ltd Back
Registered Office:
Plot No.1 City Sarve No.1537/A,Jetalpur Rd Gokak Mill Compoun, Vadodara - 390020, Gujarat, India. Phone : +91 265 298 4800   Fax:
Email :
Website :
Initial public offering of up to 2,20,00,000 equity shares of face value of Rs. 2/- each ("Equity Shares") of the company for cash at a price of Rs. 108 - Rs. 114 per equity share (including a Share Premium of Rs. 106 - Rs. 112 per Equity Share) ("Issue Price") aggregating up to Rs. 237.6 - Rs. 250.8 crores ("Issue"). The issue shall constitute [*] % of the post-issue paid-up equity share capital of the company. Price Band: Rs. 108 to Rs. 114 per equity share of face value of Rs. 2 each. The floor price is 54 times the face value of the equity shares and the cap price is 57 times the face value of the equity shares. Bids can be made for a minimum of 128 equity shares of face value of Rs. 2 each and in multiples of 128 equity shares of face value of Rs. 2 each thereafter.
Issue
Opens On Closes On
22-Dec-25 24-Dec-25
Money Payable On
Application Allotment
108.00 0.00
Minimum Application for shares in Nos : 128 Further Multiples of : 128
(₹)(Cr.) Lead Managers to the Issue
Project Cost (₹) 0.00 Nirbhay Capital Services Pvt ltd
Project Financed through Current Offer (₹) 237.60  
Post Issue Equity Share Capital (₹) 15.77  
Issue Price (₹) 108.00  
Projects
Proposed acquisition of Parekhs Hospital at Ahmedabad
Part-payment of purchase consideration for the already acquired "Ashwini Medical Centre"
Funding of capital expenditure requirements of the company towards setting up of a new hospital in Vadodara
Buying robotics equipment for the hospital Gujarat Kidney & Super Speciality hospital in Vadodara Location
Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by the company
Acquisition of additional shareholding in the subsidiary namely "Harmony Medicare Private Limited" at Bharuch
Funding inorganic growth through unidentified acquisitions and General corporate Purposes
Promoted By
Pragnesh Yashwantsinh Bharpoda
Bhartiben Pragnesh Bharpoda
Yashwantsingh Motisingh Bharpo
Listing At
BSE
NSE
Registrar to the Issue

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal (https://scores.sebi.gov.in),
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.